Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a promising clinical-stage biotechnology company with a strong potential for success due to their product candidate, Neflamapimod, which has shown promise in treating age-related neurologic disorders by improving synaptic dysfunction. The company's financials and key data metrics, including a 12-month target price of $25 per share and a $410M total enterprise value, further support this positive outlook, with risks including delays in clinical trials and regulatory approvals. Additionally, recent MRI data and improved functional connectivity further strengthen the potential for success and likely market uptake of neflamapimod.

Bears say

CervoMed is facing significant risks in its path towards Phase 3 development and potential commercialization of neflamapimod for DLB. These include uncertainties in clinical trials and regulatory approval, lack of partnerships and potential financing struggles, and competition in the market for neurologic disorder treatments. Additionally, the company still needs to clarify the benefit of neflamapimod in patients without AD co-pathology, a crucial factor in its success as a treatment.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.